Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Basuyau

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Cancer|December 15, 1988
Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysisB Chevallier, F Heintzmann, V Mosseri, et al.
BMJ (Clinical Research Ed.)|June 2, 1990
Low molecular weight heparins and hypoaldosteronismH Levesque, S Verdier, N Cailleux, et al.
Bulletin Du Cancer|April 1, 1994
[PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study]G Besse, F Kwiatkowski, G Gaillard, et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|November 14, 2012
[Prophylactic prescription of vitamin D in France: national multicenter epidemiological study of 3240 children under 6 years of age]E Mallet, J Gaudelus, P Reinert, et al.
Presse Medicale (Paris, France : 1983)|January 9, 2001
[Standards, options, and recommendations for initial management of patients with malignant ovarian epithelial tumors]P Kerbrat, C Lhommé, B Fervers, et al.
European Journal of Haematology|January 1, 1996
Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM)O Mejjad, X Le Loët, J P Basuyau, et al.
Bulletin Du Cancer|October 2, 2001
[Standards, options and recommendations for blood tumor markers in thyroid cancers]M F Pichon, J P Basuyau, G Gory-Delabaere, et al.
British Journal of Cancer|June 1, 1996
Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancersM F Pichon, P Broet, H Magdelenat, et al.
Bulletin Du Cancer|November 21, 2000
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Annales De Biologie Clinique|April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]J M Riedinger, N Eche, J P Basuyau, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Cancer|December 15, 1988
Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysisB Chevallier, F Heintzmann, V Mosseri, et al.
BMJ (Clinical Research Ed.)|June 2, 1990
Low molecular weight heparins and hypoaldosteronismH Levesque, S Verdier, N Cailleux, et al.
Bulletin Du Cancer|April 1, 1994
[PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study]G Besse, F Kwiatkowski, G Gaillard, et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|November 14, 2012
[Prophylactic prescription of vitamin D in France: national multicenter epidemiological study of 3240 children under 6 years of age]E Mallet, J Gaudelus, P Reinert, et al.
Presse Medicale (Paris, France : 1983)|January 9, 2001
[Standards, options, and recommendations for initial management of patients with malignant ovarian epithelial tumors]P Kerbrat, C Lhommé, B Fervers, et al.
European Journal of Haematology|January 1, 1996
Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM)O Mejjad, X Le Loët, J P Basuyau, et al.
Bulletin Du Cancer|October 2, 2001
[Standards, options and recommendations for blood tumor markers in thyroid cancers]M F Pichon, J P Basuyau, G Gory-Delabaere, et al.
British Journal of Cancer|June 1, 1996
Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancersM F Pichon, P Broet, H Magdelenat, et al.
Bulletin Du Cancer|November 21, 2000
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Annales De Biologie Clinique|April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]J M Riedinger, N Eche, J P Basuyau, et al.
Pageof 8